drugset / Trial / NCT00335179

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179

Phase 2 Completed 17 enrolled Graceway Pharmaceuticals, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin cells should also be visible using a special microscope. This study examines both types of changes.

Timeline

Start
2003-01
Primary completion
2003-07
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imiquimod Other / unclassified 12.5 mg Topical

Indications